Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab.

Pawlitzki M, Teuber J, Campe C, Wagner M, Schuart C, Paul F, Bittner D.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 9;5(5):e475. doi: 10.1212/NXI.0000000000000475. eCollection 2018 Sep. No abstract available.

2.

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.

Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B.

J Neuroinflammation. 2018 Mar 19;15(1):88. doi: 10.1186/s12974-018-1108-6.

3.

Loss of corticospinal tract integrity in early MS disease stages.

Pawlitzki M, Neumann J, Kaufmann J, Heidel J, Stadler E, Sweeney-Reed C, Sailer M, Schreiber S.

Neurol Neuroimmunol Neuroinflamm. 2017 Sep 25;4(6):e399. doi: 10.1212/NXI.0000000000000399. eCollection 2017 Nov.

4.

ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports.

Körtvélyessy P, Breu M, Pawlitzki M, Metz I, Heinze HJ, Matzke M, Mawrin C, Rommer P, Kovacs GG, Mitter C, Reindl M, Brück W, Wandinger KP, Lassmann H, Höftberger R, Leypoldt F.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 14;4(3):e335. doi: 10.1212/NXI.0000000000000335. eCollection 2017 May. No abstract available.

Supplemental Content

Loading ...
Support Center